Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

@inproceedings{Rini2014HypertensionAP,
  title={Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial},
  author={Brian I. Rini and David I Quinn and Michael S. Baum and Laura S. Wood and Jamal Christo Tarazi and Brad Rosbrook and Lillian Shahied Arruda and Laura A Cisar and Walter Gregory Roberts and Sinil Kim and Robert J Motzer},
  booktitle={Targeted Oncology},
  year={2014}
}
Inhibitors of the vascular endothelial growth factor (VEGF) pathway frequently induce hypertension when used to treat patients with advanced renal cell carcinoma (RCC). This analysis characterizes hypertension and hypertension-related events in patients treated with the VEGF pathway inhibitors axitinib or sorafenib in the AXIS trial. AXIS was a randomized phase III study of axitinib versus sorafenib in patients with metastatic RCC following failure of one prior systemic regimen. Patients with… CONTINUE READING
18 Extracted Citations
29 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 18 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 29 references

the impact on long-term use

  • Kirkali Z Adverse events from targeted therapies in advanc carcinoma
  • BJU Int 107:1722– 1732 Targ Oncol
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…